2026-04-27T21:40:18Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/453012021-06-24T07:25:59Zcom_10324_41462com_10324_954com_10324_894col_10324_41463

Pérez Rubio, Alberto Luquero Alcalde, Francisco Javier Bachiller Luque, María Rosario Torre Pardo, Paz de la Eiros Bouza, José María Producción Científica Rotavirus vaccines (RV) have decreased the infant morbidity and mortality in countries that included RV in their national schedule. Rotavirus vaccination is recommended by the Spanish Society of Pediatrics; however, Spain, as most countries in Europe, has authorized commercialization but not included RV in its national vaccination program. We assessed the impact of RV on the rotavirus hospitalization rate through an interrupted time series analysis. There was a 46.8% (95% CI: 29.3–60.2) decrease on the rotavirus hospitalizations rate in the study region after RV commercialization in 2006. Currently there is limited evidence about the impact of RV in Europe, especially among countries not offering systematic vaccination in their national schedule. Documentation of RV coverage, effectiveness and impact is urgently needed in these countries. 2021-02-18 2021-02-18 2016 info:eu-repo/semantics/article Trials in Vaccinology, 2016, vol. 5, p. 84-87 1879-4378 http://uvadoc.uva.es/handle/10324/45301 10.1016/j.trivac.2016.04.005 84 87 Trials in Vaccinology 5 eng https://www.sciencedirect.com/science/article/pii/S1879437816300109 info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ © 2016 Published by Elsevier Ltd. Attribution-NonCommercial-NoDerivatives 4.0 Internacional Elsevier